Beta Bionics (NASDAQ:BBNX) Trading 8.2% Higher – Here’s What Happened

Beta Bionics, Inc. (NASDAQ:BBNX)’s share price was up 8.2% during trading on Thursday . The stock traded as high as $13.25 and last traded at $13.4730. Approximately 81,004 shares changed hands during trading, a decline of 93% from the average daily volume of 1,131,098 shares. The stock had previously closed at $12.45.

Key Headlines Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Negative Sentiment: Johnson Fistel announced an investigation into Beta Bionics over possible federal securities-law violations and investor losses, citing slower new patient start growth as a key concern. Article Title
• Negative Sentiment: Robbins LLP also said it is investigating Beta Bionics’ officers and directors for possible securities-law violations and breaches of fiduciary duty, adding to legal risk for shareholders. Article Title
• Neutral Sentiment: Several executives, including CFO Stephen Feider and insiders Steven Jon Russell, Mark Hopman, and Mike Mensinger, sold shares on June 2, but the company said the transactions were tied to tax withholding on vested equity awards rather than discretionary selling.
• Positive Sentiment: Beta Bionics recently highlighted near real-time public reporting of real-world data for its iLet Bionic Pancreas, which may support investor confidence in the company’s commercialization and transparency efforts.

Analyst Ratings Changes

Several equities analysts have commented on BBNX shares. Stifel Nicolaus lowered their target price on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. Bank of America lowered their target price on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research report on Monday, May 18th. UBS Group raised shares of Beta Bionics to a “strong-buy” rating in a research report on Monday, February 9th. Robert W. Baird lowered their target price on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Finally, Wall Street Zen cut shares of Beta Bionics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $19.70.

Beta Bionics Price Performance

The stock’s fifty day simple moving average is $10.83 and its 200-day simple moving average is $17.31. The company has a market capitalization of $601.25 million, a P/E ratio of -8.91 and a beta of 3.40.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The company had revenue of $27.63 million during the quarter. On average, research analysts predict that Beta Bionics, Inc. will post -2.19 earnings per share for the current year.

Insider Activity

In related news, insider Steven Jon Russell sold 4,222 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total value of $53,239.42. Following the completion of the sale, the insider owned 173,849 shares in the company, valued at approximately $2,192,235.89. This trade represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Stephen Feider sold 6,676 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total transaction of $84,184.36. Following the completion of the sale, the chief financial officer owned 166,053 shares of the company’s stock, valued at approximately $2,093,928.33. The trade was a 3.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 24,601 shares of company stock valued at $300,847 over the last three months. 5.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Beta Bionics

Several hedge funds have recently made changes to their positions in BBNX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Beta Bionics in the first quarter valued at about $95,000. Goldman Sachs Group Inc. bought a new stake in shares of Beta Bionics in the first quarter valued at about $715,000. Woodline Partners LP bought a new stake in shares of Beta Bionics in the first quarter valued at about $1,530,000. Strs Ohio bought a new stake in shares of Beta Bionics in the first quarter valued at about $29,000. Finally, Rhumbline Advisers bought a new stake in shares of Beta Bionics in the first quarter valued at about $158,000.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual?hormone modes.